2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Over the past quarter century, clinical trials have consistently demonstrated that lowering levels of low-density lipoprotein cholesterol (LDL-C) with statins reduces the rate of major adverse cardiovascular events. However, the findings that many patients continue to experience events or harbour inappropriately high LDL-C levels despite intensive statin therapy and the clinical reality of statin intolerance suggests that additional therapeutic strategies are required in order to achieve more effective reductions in cardiovascular risk. The emergence of inhibitory monoclonal antibodies targeted against proprotein convertase subtilisin kexin type 9 (PCSK9) provides a novel approach to reducing LDL-C levels. The current experience of PCSK9 inhibitors and implications for clinical use and cost effectiveness will be reviewed.

          Related collections

          Author and article information

          Journal
          Intern Med J
          Internal medicine journal
          Wiley-Blackwell
          1445-5994
          1444-0903
          Aug 2017
          : 47
          : 8
          Affiliations
          [1 ] South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia.
          Article
          10.1111/imj.13451
          28401639
          99b907ec-da0e-48d6-b4a1-460a479f06d9
          History

          PCSK9 inhibitors,atherosclerosis,cardiovascular risk,lipids

          Comments

          Comment on this article